nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.12.2006 | Original article

FDG—a marker of tumour hypoxia? A comparison with [¹⁸F]fluoromisonidazole and pO₂-polarography in metastatic head and neck cancer

verfasst von: Michael Zimny, Bernd Gagel, Ercole DiMartino, Kurt Hamacher, Heinz H. Coenen, Martin Westhofen, Michael Eble, Ulrich Buell, Patrick Reinartz

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 12/2006

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Experimental data suggest that the accumulation of [¹⁸F]fluorodeoxyglucose (FDG) in malignant tumours is related to regional hypoxia. The aim of this study was to evaluate the clinical potential of FDG positron emission tomography (PET) to assess tumour hypoxia in comparison with [¹⁸F]fluoromisonidazole (FMISO) PET and pO₂-polarography.

Methods

Twenty-four patients with head and neck malignancies underwent FDG PET, FMISO PET, and pO₂-polarography within 1 week. Parameters of pO₂-polarography were the relative frequency of pO₂ readings ≤2.5 mmHg, ≤5 mmHg and ≤10 mmHg, respectively, as well as the mean and median pO₂.

Results

We observed a moderate correlation of the maximum standardised uptake value (SUV) of FDG with the tumour to blood ratio of FMISO at 2 h (R=0.53, p<0.05). However, SUV of FDG was similar in hypoxic and normoxic tumours as defined by pO₂-polarography (6.9±3.2 vs 6.2±3.0, NS), and the FDG uptake was not correlated with the results of pO₂-polarography. The retention of FMISO was significantly higher in hypoxic tumours than in normoxic tumours (tumour to muscle ratio at 2 h: 1.8±0.4 vs 1.4±0.1, p<0.05), and the FMISO tumour to muscle ratio showed a strong correlation with the frequency of pO₂ readings ≤5 mmHg (R=0.80, p<0.001).

Conclusion

These results support the hypothesis that tumour hypoxia has an effect on glucose metabolism. However, other factors affecting FDG uptake may be more predominant in chronic hypoxia, and thus FDG PET cannot reliably differentiate hypoxic from normoxic tumours.

Wouters BG, Weppler SA, Koritzinsky M, Landuyt W, Nuyts S, Theys J, et al. Hypoxia as a target for combined modality treatments. Eur J Cancer 2002;38:240–257PubMedCrossRef

Vaupel P, Harrison L. Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist 2004;9(Suppl 5):4–9PubMedCrossRef

Brizel DM, Dodge RK, Clough RW, Dewhirst MW. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol 1999;53:113–117PubMedCrossRef

Gray LH, Conger AD, Ebert M, Hornsey S, Scott OC. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953;26:638–648PubMedCrossRef

Vaupel P, Schlenger K, Knoop C, Hockel M. Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O₂ tension measurements. Cancer Res 1991;51:3316–3322PubMed

Mueller-Klieser W, Schlenger KH, Walenta S, Gross M, Karbach U, Hoeckel M, et al. Pathophysiological approaches to identifying tumor hypoxia in patients. Radiother Oncol 1991;20(Suppl 1):21–28PubMedCrossRef

Hockel M, Knoop C, Schlenger K, Vorndran B, Baussmann E, Mitze M, et al. Intratumoral pO₂ predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 1993;26:45–50PubMedCrossRef

Nordsmark M, Bentzen SM, Rudat V, Brizel D, Lartigau E, Stadler P, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 2005;77:18–24PubMedCrossRef

Koh WJ, Rasey JS, Evans ML, Grierson JR, Lewellen TK, Graham MM, et al. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int J Radiat Oncol Biol Phys 1992;22:199–212PubMed

10.

Koh WJ, Bergman KS, Rasey JS, Peterson LM, Evans ML, Graham MM, et al. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys 1995;33:391–398PubMedCrossRef

11.

Rasey JS, Koh WJ, Evans ML, Peterson LM, Lewellen TK, Graham MM, et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [¹⁸F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 1996;36:417–428PubMedCrossRef

12.

Yeh SH, Liu RS, Wu LC, Yang DJ, Yen SH, Chang CW, et al. Fluorine-18 fluoromisonidazole tumour to muscle retention ratio for the detection of hypoxia in nasopharyngeal carcinoma. Eur J Nucl Med 1996;23:1378–1383PubMedCrossRef

13.

Hicks RJ, Rischin D, Fisher R, Binns D, Scott AM, Peters LJ. Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent. Eur J Nucl Med Mol Imaging 2005;32:1384–1391PubMedCrossRef

14.

Hodgkiss RJ. Use of 2-nitroimidazoles as bioreductive markers for tumour hypoxia. Anticancer Drug Des 1998;13:687–702PubMed

15.

Chapman JD, Baer K, Lee J. Characteristics of the metabolism-induced binding of misonidazole to hypoxic mammalian cells. Cancer Res 1983;43:1523–1528PubMed

16.

Piert M, Machulla H, Becker G, Stahlschmidt A, Patt M, Aldinger P, et al. Introducing fluorine-18 fluoromisonidazole positron emission tomography for the localisation and quantification of pig liver hypoxia. Eur J Nucl Med 1999;26:95–109PubMedCrossRef

17.

Gagel B, Reinartz P, Dimartino E, Zimny M, Pinkawa M, Maneschi P, et al. pO₂ polarography versus positron emission tomography ([¹⁸F]fluoromisonidazole, [¹⁸F]-2-fluoro-2′-deoxyglucose). An appraisal of radiotherapeutically relevant hypoxia. Strahlenther Onkol 2004;180:616–622PubMedCrossRef

18.

Kallinowski F, Brownell AL, Vaupel P, Brownell GL. Combined tissue oxygen tension measurement and positron emission tomography studies on glucose utilization in oncogene-transformed cell line tumour xenografts in nude mice. Br J Radiol 1991;64:350–359PubMedCrossRef

19.

Clavo AC, Brown RS, Wahl RL. Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. J Nucl Med 1995;36:1625–1632PubMed

20.

Minn H, Clavo AC, Wahl RL. Influence of hypoxia on tracer accumulation in squamous-cell carcinoma: in vitro evaluation for PET imaging. Nucl Med Biol 1996;23:941–946PubMedCrossRef

21.

Pugachev A, Ruan S, Carlin S, Larson SM, Campa J, Ling CC, et al. Dependence of FDG uptake on tumor microenvironment. Int J Radiat Oncol Biol Phys 2005;62:545–553PubMedCrossRef

22.

Rajendran JG, Mankoff DA, O’Sullivan F, Peterson LM, Schwartz DL, Conrad EU, et al. Hypoxia and glucose metabolism in malignant tumors: evaluation by [¹⁸F]fluoromisonidazole and [¹⁸F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res 2004;10:2245–2252PubMedCrossRef

23.

Zhao S, Kuge Y, Mochizuki T, Takahashi T, Nakada K, Sato M, et al. Biologic correlates of intratumoral heterogeneity in¹⁸F-FDG distribution with regional expression of glucose transporters and hexokinase-II in experimental tumor. J Nucl Med 2005;46:675–682PubMed

24.

Hudson HM, Larkin RS. Accelerated image reconstruction using ordered subsets of projection data. IEEE Trans Med Imaging 1994;13:601–609CrossRefPubMed

25.

Thill R, Neuerburg J, Fabry U, Cremerius U, Wagenknecht G, Hellwig D, et al. Comparison of findings with 18-FDG PET and CT in pretherapeutic staging of malignant lymphoma. Nuklearmedizin 1997;36:234–239PubMed

26.

Zimny M, Schröder W, Wolters S, Cremerius U, Rath W, Büll U.¹⁸F-fluorodeoxyglucose PET in ovarian carcinoma: methodology and preliminary results. Nuklearmedizin 1997;36:228–233PubMed

27.

Rajendran JG, Wilson DC, Conrad EU, Peterson LM, Bruckner JD, Rasey JS, et al. [¹⁸F]FMISO and [¹⁸F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression. Eur J Nucl Med Mol Imaging 2003;30:695–704PubMedCrossRef

28.

Bentzen L, Keiding S, Horsman MR, Falborg L, Hansen SB, Overgaard J. Feasibility of detecting hypoxia in experimental mouse tumours with¹⁸F-fluorinated tracers and positron emission tomography—a study evaluating [¹⁸F]fluoro-2-deoxy-D-glucose. Acta Oncol 2000;39:629–637PubMedCrossRef

29.

Sorensen M, Horsman MR, Cumming P, Munk OL, Keiding S. Effect of intratumoral heterogeneity in oxygenation status on FMISO PET, autoradiography, and electrode Po2 measurements in murine tumors. Int J Radiat Oncol Biol Phys 2005;62:854–861PubMedCrossRef

30.

Minn H, Clavo AC, Wahl RL. Influence of hypoxia on tracer accumulation in squamous-cell carcinoma: in vitro evaluation for PET imaging. Nucl Med Biol 1996;23:941–946PubMedCrossRef

31.

Burgman P, Odonoghue JA, Humm JL, Ling CC. Hypoxia-Induced increase in FDG uptake in MCF7 cells. J Nucl Med 2001;42:170–175PubMed

32.

Evans SM, Hahn SM, Magarelli DP, Koch CJ. Hypoxic heterogeneity in human tumors: EF5 binding, vasculature, necrosis, and proliferation. Am J Clin Oncol 2001;24:467–472PubMedCrossRef

33.

Bos R, van der Hoeven JJ, van der Wall E, van der Groep P, van Diest PJ, Comans EF, et al. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 2002;20:379–387PubMedCrossRef

34.

Semenza GL. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 2002;8:S62–S67PubMedCrossRef

35.

Lim JH, Lee ES, You HJ, Lee JW, Park JW, Chun YS. Ras-dependent induction of HIF-1alpha785 via the Raf/MEK/ERK pathway: a novel mechanism of Ras-mediated tumor promotion. Oncogene 2004;23:9427–9431PubMedCrossRef

36.

Lawrentschuk N, Poon AM, Foo SS, Putra LG, Murone C, Davis ID, et al. Assessing regional hypoxia in human renal tumours using¹⁸F-fluoromisonidazole positron emission tomography. BJU Int 2005;96:540–546PubMedCrossRef

37.

Movsas B, Chapman JD, Greenberg RE, Hanlon AL, Horwitz EM, Pinover WH, et al. Increasing levels of hypoxia in prostate carcinoma correlate significantly with increasing clinical stage and patient age: an Eppendorf pO₂ study. Cancer 2000;89:2018–2024PubMedCrossRef

38.

Sauer G, Weber KJ, Peschke P, Eble MJ. Measurement of hypoxia using the comet assay correlates with preirradiation microelectrode pO₂ histography in R3327-AT rodent tumors. Radiat Res 2000;154:439–446PubMedCrossRef

39.

Milross CG, Tucker SL, Mason KA, Hunter NR, Peters LJ, Milas L. The effect of tumor size on necrosis and polarographically measured pO₂. Acta Oncol 1997;36:183–189PubMed

Titel: FDG—a marker of tumour hypoxia? A comparison with [18F]fluoromisonidazole and pO2-polarography in metastatic head and neck cancer
verfasst von: Michael Zimny
Bernd Gagel
Ercole DiMartino
Kurt Hamacher
Heinz H. Coenen
Martin Westhofen
Michael Eble
Ulrich Buell
Patrick Reinartz
Publikationsdatum: 01.12.2006
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 12/2006
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-006-0175-6

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2006

Comparative benefits and limitations of 18F-FDG PET and CT-MRI in documented or suspected recurrent cervical cancer

Prevalence of myocardial ischaemia as assessed with myocardial perfusion scintigraphy in patients with diabetes mellitus type 2 and mild anginal symptoms

Predictive value of 99mTc-sestamibi scintigraphy for healing of extremity amputation

Data acquisition and analysis: the strength of methodology in nuclear medicine and molecular imaging

Successful high-resolution animal positron emission tomography of human Ewing tumours and their metastases in a murine xenograft model

Incidental finding of an 11C-choline PET-positive solitary plasmacytoma lesion